|
Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC). |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Roche Pharma AG; Teva |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Proacta |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Proacta |
| |
|
|
|
| |
|
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Novartis; Roche/Genentech |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Lilly |
Honoraria - Lilly; Roche Pharma AG; Sanofi |
Consulting or Advisory Role - Lilly; Roche Pharma AG; Sanofi |
Research Funding - AstraZeneca; Roche Pharma AG; Sanofi |
|
Travel, Accommodations, Expenses - Roche Pharma AG; Sanofi |
| |
|
|
Stock and Other Ownership Interests - Lilly |
| |
|
|
Stock and Other Ownership Interests - Lilly |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Boehringer Ingelheim (Inst) |
Research Funding - AstraZeneca (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst) |